• 제목/요약/키워드: Non-cancer patient

검색결과 574건 처리시간 0.029초

Effects of Doctor-patient Communication on Quality of Life among Breast Cancer Patients in Southern China

  • Zhou, Qin;Shen, Ji-Chuan;Liu, Ying-Zhi;Lin, Guo-Zhen;Dong, Hang;Li, Ke
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권14호
    • /
    • pp.5639-5644
    • /
    • 2014
  • Objective: This study aimed to determine effects of doctor-patient communication on the quality of life among breast cancer survivors in 16 communities in southern China. Methods: Multistage random sampling was to use to recruit 260 females from the Guangzhou Cancer Registry Database who were diagnosed with breast cancer. A questionnaire provided data on the doctor-patient communication (including the doctor's attitude, the patient's participation with the medical decision and information about the disease) and QOL (quality of life), as measured using FACT-B. Univariate analysis, non-conditional logistic regression was used to evaluate the associations between the doctor-patient communication and QOL. Results: Females who received good attitudes from doctors demonstrated higher FACT-B (OR=4.65, 95% CI: 1.68-12.86), social well-being (OR=5.88, 95% CI: 2.16-16.05), emotional well-being (OR=4.77, 95% CI: 1.92-11.88), and functional well-being ((OR=5.26, 95% CI: 1.90-14.52) compared to the females who encountered worse attitudes from their doctor, adjusting for age, education, marriage, employment, family income, years since diagnosis, TNM stage, radiation therapy, chemotherapy and side effects, particularly when the TNM stage was 0-II and the patients exhibited no side effects. Regardless of the length of time after diagnosis, doctors' good attitudes resulted in higher QOL scores. Conclusions: This study demonstrated that the doctor-patient communication has a significant association with the QOL of breast cancer survivors, mainly dependent on the doctors' attitude. Effective intervention is required to develop optimal doctor-patient communication.

비소세포성 폐암 환자의 항암화학요법을 위한 Critical Pathway개발과 적용효과 (Development of a Critical Pathway for the Chemotherapy of Non-small Cell Lung Cancer Patients and Its Effects)

  • 최자윤;장금성;최은영
    • 간호행정학회지
    • /
    • 제8권1호
    • /
    • pp.85-95
    • /
    • 2002
  • The purpose of this study was to develope a critical pathway for the chemotherapy of non-small cell lung cancer patients and to identify its effects after implementation. Critical pathway was developed through 5 steps including content and clinical validity tests with collaborative efforts of nurses, clinicians, and other allied healthcare professionals with the aim of improving the quality of patient care, while minimizing cost to the patients. This paper was described an evaluation of the impact of a developed critical pathway on complication rate, length of stay, costs, the interval of treatment and patient satisfaction by nonequivalent control group posttest-only non-synchronized research design.Results were compared between the two groups of patients. There were no significant differences in demographic variables and the occurrence of bone marrow suppression between experimental group and control group(t=-0.01, p=0.992). There were statistically significant decreases in the average length of stay(t=-10.45, p=0.000), in the average cost(t=-2.988, p=0.004), and in the interval of treatment(t=-6.75, p=0.000) after implementation of the critical pathway compared to control group. Also, there was a statistically significant improvement of the patient satisfaction after implementation of the critical pathway compared to control group(t=4.57, p=0.000). This paper concludes that critical pathway in chemotherapy for lung cancer, implemented in the context of an general hospital, is the useful tool to shorten the hospital stay, reduce treatment costs, and improve the quality of life in cancer patients. Further study needs to be conducted to identify other clinical outcomes including job satisfaction, collaboration among health professionals and potential for use in education. Also, it is recommended that nurses should revise continuously the developed critical pathway through clinical implementation and maintain their role of patient advocacy through monitoring pathway compliance.

  • PDF

비소세포성 폐암의 척추 전이로 발생한 암성통증에 대한 초오 약침을 포함한 한방 치료 1례 (A Case Report of a Non-small Cell Lung Cancer Patient Metastasis to Vertebra with Cancer Pain Improved by Traditional Korean medicine including Aconitum Ciliare Decaisne Pharmacopuncture)

  • 윤미정;조나경;이유리;최홍식;김승모;김경순
    • 대한암한의학회지
    • /
    • 제24권2호
    • /
    • pp.33-41
    • /
    • 2019
  • Objectives : The purpose of this case report is to examine clinical application of Traditional Korean medicine including aconitum ciliare decaisne pharmacopuncture for cancer pain caused by bone metastasis of non small cell lung cancer. Methods : The patient diagnosed as non small cell lung cancer was treated with pharmacopuncture, acupuncture, electroacupuncture and herbal medicine. We used NRS(Numeric rating scale) and ECOG PS(Eastern Cooperative Oncology Group Performance Status) to observe the effect of the treatment. Results : After the treatment, NRS of cancer pain and ECOG PS score decreased. Also, the frequency of using rapid-onset opioids decreased. Conclusions : This study suggests Traditional Korean medicine treatment including aconitum ciliare decaisne pharmacopuncture is effective in cancer pain control caused by metastasis to bone with multiple organs with non small cell lung cancer.

알레젠 제거 옻나무 추출물 투여로 생존기간이 연장된 편평세포폐암 환자 1례 (A Case Report of Squamous Cell Lung Cancer Patient Treated with Allergen Removed Rhus Verniciflua Stokes Extract)

  • 김은희;박소정;최원철;이수경
    • 대한암한의학회지
    • /
    • 제16권2호
    • /
    • pp.35-41
    • /
    • 2011
  • Background : Lung cancer is one of the most common malignancy in the world. Types of lung cancer are Non small cell lung cancer and small cell lung cancer. Subtypes of Non small cell lung cancer are adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Knowing the type of lung cancer is important in determining both treatment and prognosis. Recently, due to newly developed anti-cancer drugs, squamous cell carcinoma has relatively poor prognosis than non-squamous cell carcinoma. Case : We report a squamous cell lung cancer case treated with allergen removed Rhus verniciflua Stokes (aRVS) extract. The patients initially diagnosed stage squamous cell lung carcinoma, but she refused recommended operation. She initiated aRVS extract monotherapy in October. 2006. The follow up Computed tomography in March. 2007, she diagnosed stable disease of tumor response on aRVS treatment. However, this case was lost to follow up for 6 months while she was treated with tomotherapy. In October 2007, she came back to our cancer center after diagnosed stage IV metastasized lung to lung, and aRVS monotherapy was restarted. She had survived 2 years after metastasis of squamous cell lung carcinoma. Conclusion : Allergen removed Rhus verniciflua Stokes(aRVS) sucessfully prolonged overall survival of a squamous cell lung cancer patient.

재발성 비소세포성 폐암환자의 Afatinib과 삼칠충초정 병용투여 경과관찰 1례 (A Case of Patient with Recurring Non-Small Cell Lung Carcinoma Treated with Samchilchoongcho-Jung in Conjunction with Afatinib)

  • 김지혜;배겨레;박소정;조종관;유화승
    • 대한한방내과학회지
    • /
    • 제38권1호
    • /
    • pp.72-80
    • /
    • 2017
  • Objective: The purpose of this study is to report the case of a patient with recurring non-small cell lung carcinoma (NSCLC) taking Samchilchoongcho-Jung with Afatinib. Methods: An NSCLC patient diagnosed with multiple bone and pulmonary metastasis was taking Afatinib (20 mg/day) and suffering from stomatitis caused by the Afatinib. The patient was treated with Samchilchoongcho-Jung (1,500 mg/ day) for 3 months. The tumor size was measured with computed tomography, and laboratory findings, including tumor markers (CEA, Cyfra 21-1), were also followed up. Stomatitis was measured by a numeric rating scale, and adverse events were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0. Results: After combined treatment, stable disease was shown on computed tomography. The tumor marker levels of CEA and Cyfra 21-1 were decreased, and the stomatitis significantly improved. NCI-CTCAE 4.0 showed no adverse events. Conclusion: This case study suggests that Samchilchoongcho-Jung may have a synergic effect, in conjunction with Afatinib, on the treatment of patients with recurring NSCLC.

양한방 협진을 통한 뇌전이 동반 말기 폐암환자 치험 1례 (Integrated Medicine Therapy for an End-stage Lung Cancer Patient with Brain Metastasis)

  • 박승찬;김도형;한창우;박성하;이인;최준용
    • 대한암한의학회지
    • /
    • 제16권2호
    • /
    • pp.43-51
    • /
    • 2011
  • 이번 증례에서 뇌전이가 동반된 IV기 비소세포성 폐암 환자에 대해 양한방 치료를 병행하여 VAS, FACT-L, FACIT-fatigue 등을 통하여 그 경과를 관찰한 바 방광자극증상 및 수면 등 삶의 질의 개선을 관찰할 수 있었다. 하지만 원활하지 못한 협진 체계로 인하여 환자 관리에 있어 문제점을 발견할 수 있었다. 향후 한방 치료를 통한 암환자 관리를 위해서는 접근성이 뛰어난 양한방 협진체계의 구축이 필수적인 것으로 사료된다.

비소세포폐암 환자에서 부종양성 증후군의 증상으로 발생한 좌측 3, 4 뇌신경마비 1예 (A Case of Cranial Nerve Palsy as a Paraneoplastic Syndrome in Non-Small Cell Lung Cancer)

  • 이영미;심우호;윤선옥;김송이;박정수;고보건;변민광;최영철;김형중
    • Tuberculosis and Respiratory Diseases
    • /
    • 제70권2호
    • /
    • pp.160-164
    • /
    • 2011
  • Paraneoplastic neurologic syndrome is a group of assorted disorders resulting from damage to the nervous system in cancer, remote from primary site, and not related to metastasis, infection, or metabolic disorder associated with cancer. Patient with small cell lung cancer sometimes shows various neurological syndromes, but patient with non-small cell lung cancer rarely shows neurologic syndromes and few antineuronal antibodies have been found. Here, we report a case of 53-year-old male patient who developed ptosis and extraocular muscular limitation of left eye due to third and forth cranial nerve palsy in non-small cell lung cancer without brain metastasis. These neurologic symptoms improved after lobectomy without any other treatment immunotherapy.

Breaking Bad News: Patient Preferences and the Role of Family Members when Delivering a Cancer Diagnosis

  • Rao, Abha;Sunil, Bhuvana;Ekstrand, Maria;Heylen, Elsa;Raju, Girish;Shet, Arun
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제17권4호
    • /
    • pp.1779-1784
    • /
    • 2016
  • Background: Western physicians tend to favour complete disclosure of a cancer diagnosis to the patient, while non-Western physicians tend to limit disclosure and include families in the process; the latter approach is prevalent in clinical oncology practice in India. Few studies, however, have examined patient preferences with respect to disclosure or the role of family members in the process. Materials and Methods: Structured interviews were conducted with patients (N=127) in the medical oncology clinic of a tertiary referral hospital in Bangalore, India. Results: Patients ranged in age from 18-88 (M=52) and were mostly male (59%). Most patients (72%) wanted disclosure of the diagnosis cancer, a preference significantly associated with higher education and English proficiency. A majority wanted their families to be involved in the process. Patients who had wanted and not wanted disclosure differed with respect to their preferences regarding the particulars of disclosure (timing, approach, individuals involved, role of family members). Almost all patients wanted more information concerning their condition, about immediate medical issues such as treatments or side effects, rather than long-term or non-medical issues. Conclusions: While most cancer patients wanted disclosure of their disease, a smaller group wished that their cancer diagnosis had not been disclosed to them. Regardless of this difference in desire for disclosure, both groups sought similar specific information regarding their cancer and largely favoured involvement of close family in decision making. Additional studies evaluating the influence of factors such as disease stage or family relationships could help guide physicians when breaking bad news.

노봉상기정을 투여하여 Olmutinib으로 인한 피부염이 호전된 4기 비소세포성 폐암 환자 1례 (A Case of Non-Small Cell Lung Carcinoma Patient Who Improved Skin Rash Due to Olmutinib by Administration of Nobongsangki-Jeong)

  • 최유나;김지혜;배겨레;조종관;유화승
    • 대한암한의학회지
    • /
    • 제22권1호
    • /
    • pp.13-22
    • /
    • 2017
  • Objective: The purpose of this study is to report the effect of Nobongsangki-Jeong on skin rash caused by Olmutinib. Methods: A female Non-Small cell lung carcinoma patient (Adenocarcinoma, Stage IV, Epidermal Growth Factor Receptor positive) suffered from skin rash due to the side effect of Olmutinib administration. She was treated with Nobongsangki-Jeong for the symptom management for 14 days. The clinical outcomes were measured by numeric rating scale (NRS) and National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Results: After treatment, skin rash was improved from NRS 5 to 1. Pruritus and pain of skin were improved from NCI-CTCAE grade 2 to 1. Conclusion: This case study suggests that Nobongsangki-Jeong may have the efficacy for the treatment of skin rash caused by Olmutinib.

Levels of Tobacco-specific Metabolites among Non-smoking Lung Cancer Cases at Diagnosis: Case-control Findings

  • Hwang, Sang-Hyun;Ryu, Hye-Jung;Kang, Soo Jin;Yun, E. Hwa;Lim, Min Kyung;Kim, Heung Tae;Lee, Jin Soo;Lee, Do-Hoon
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권11호
    • /
    • pp.6591-6593
    • /
    • 2013
  • Background: Environmental tobacco smoking (ETS) significantly contributes to morbidity and mortality and is a known risk factor for lung cancer development in lifelong nonsmokers. The metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its glucuronides (NNAL-Glucs) have now emerged as leading biomarkers for the study of carcinogen exposure in non-smokers exposed to ETS. Materials and Methods: We carried out our study on NNAL in the urine of non-smokers exposed to ETS and the association between ETS and lung cancer. Subjects were enrolled from 2008-2010. NNAL was analyzed for 74 non-smoking lung cancer and 85 healthy controls. The main objective of this study was to provide an estimate of the risk of lung cancer from exposure to ETS in the Korean population. Results: The mean NNAL concentration in urine was significantly lower in non-smoking patient groups (n=74) than in control groups (n=85) ($4.7{\pm}15.0$ pg/mg, $6.5{\pm}17.9$ pg/mg, respectively, Mann-Whitney U test, p<0.001). Conclusions: The urine NNAL of non-smoking patients with lung cancer was not elevated with regard to the non-smoking control group. This may be due to life-style changes after diagnosis. A prospective study will be needed to evaluate the association of NNAL and non-smoking lung cancer.